{"created":"2023-06-19T10:30:50.176674+00:00","id":2988,"links":{},"metadata":{"_buckets":{"deposit":"6140b7d5-155a-4202-b842-211384e5b7f6"},"_deposit":{"created_by":31,"id":"2988","owners":[31],"pid":{"revision_id":0,"type":"depid","value":"2988"},"status":"published"},"_oai":{"id":"oai:kwmed.repo.nii.ac.jp:00002988","sets":["1709617079800:35:800"]},"author_link":["130679","130680","130681","130682","130683","130684","130685","130686","130687","130688","130689","130690","130691","130692"],"item_10001_alternative_title_1":{"attribute_name":"その他(別言語等)のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"A case of unresectable microsatellite stable colon cancer with hyper progressive disease due to initiation of nivolumab based on the result as tumor mutational burden high","subitem_alternative_title_language":"en"}]},"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"67","bibliographicPageStart":"61","bibliographicVolumeNumber":"47","bibliographic_titles":[{"bibliographic_title":"川崎医学会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Kawasaki medical journal","bibliographic_titleLang":"en"}]}]},"item_10001_description_33":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_description":"症例報告","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10001_description_34":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_description":"Case Report","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"川崎医学会","subitem_publisher_language":"ja"}]},"item_10001_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.11482/KMJ-J202147061","subitem_relation_type_select":"DOI"}}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2021/KMJ-J202147061.pdf","subitem_relation_type_select":"URI"}}]},"item_10001_relation_35":{"attribute_name":"医中誌ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"2022194413","subitem_relation_type_select":"ICHUSHI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00045593","subitem_source_identifier_type":"NCID"},{"subitem_source_identifier":"AN12940574","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0386-5924","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2758-089X","subitem_source_identifier_type":"EISSN"}]},"item_10001_text_31":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学臨床腫瘍学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学臨床腫瘍学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学臨床腫瘍学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学臨床腫瘍学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学臨床腫瘍学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学臨床腫瘍学"},{"subitem_text_language":"ja","subitem_text_value":"川崎医科大学臨床腫瘍学"}]},"item_10001_text_32":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Clinical Oncology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Clinical Oncology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Clinical Oncology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Clinical Oncology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Clinical Oncology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Clinical Oncology, Kawasaki Medical School"},{"subitem_text_language":"en","subitem_text_value":"Department of Clinical Oncology, Kawasaki Medical School"}]},"item_10001_textarea_5":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_textarea_language":"en","subitem_textarea_value":"　Cancer gene panel test is a companion diagnostic tool to identify the patients who will benefit from target therapies in relation to gene mutations detected by using next-generation sequencer procedures. Herein we report a case of microsatellite stable colorectal cancer who was diagnosed as tumor mutational burden-high by the Foundation One CDx, and thus, led to treat to nivolumab. \n　A male at his age 50s visited our hospital with a chief complaint of fatigue and epigastric pain, and was diagnosed with unresectable advanced sigmoid colon cancer; cStage IVB (cT3cN3cH3cM1b [multiple lung and liver metastases]). The primary tumor possessed neither RAS nor BRAF gene mutation. The patient was sequentially treated through the 1st -line to the 5th -line. At the start of the 6th -line, the Foundation One CDx as well as microsatellite instability (MSI) test was evaluated. The primary tumor possessed no MSI feature but tumor mutational burden (TMB)-high (18b/Mb). Thus, the patient enrolled a clinical trial of nivolumab and received nivolumab monotherapy. Unfortunately, he developed hyper progressive disease (HPD) and died 2 months after induction of nivolumab. In this case, the Foundation One CDx was performed a little later, but as a result, delay of this cancer gene panel test might had made his life the longer. In this way, it is necessary to carry out cancer gene panel tests with the understanding that participation in indications for new drugs does not always lead to the expected results."}]},"item_10001_textarea_6":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_textarea_language":"ja","subitem_textarea_value":"　がん遺伝子パネル検査は，次世代シークエンサーにより多数のがん関連遺伝子を網羅的に検索し，検出された遺伝子変異に対する治療による恩恵を受ける可能性のある患者を特定するためのコンパニオン診断である．今回我々は FoundationOne CDx がんゲノムプロファイルにて tumor mutational burden 高値（TMB-high）が判明し，nivolumab 導入に至ったマイクロサテライト安定大腸癌の一例を経験したので報告する． 　\n　症例は50代男性．20XX年10月に倦怠感，心窩部痛を主訴に来院し，S状結腸癌 cT3cN3cH3cM1b（多 発肺，肝），cStage Ⅳ B，RAS-BRAF 遺伝子変異陰性と診断された．標準治療及び臨床試験参加を含め，一次治療から五次治療を行い，六次治療導入時に microsatellite instability（MSI）検査及びがん遺伝子パネル検査を行ったところ，MSI は陰性であったがTMB-high と判定されたため， nivolumab の臨床治験に参加した．しかし，nivolumab 単剤投与１コース施行後に急速な肝転移の 増大と肝不全を認め，nivolumab 開始から約２か月後に永眠された．後方視解析により，本患者は nivolumab により hyper progressive disease（HPD）が誘導されたと考えられた．本症例は，がん遺伝子パネル検査施行時期がやや遅れたことは否めないが，結果的には，この検査施行時期がやや遅れたことが，余命延長に寄与している．このように，新規薬剤への適応参加が必ずしも期待される結果に至らないことを理解して，がん遺伝子パネル検査を行う必要がある．"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"堅田, 洋佑","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"永坂, 岳司","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"佐野, 史典","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"谷岡, 洋亮","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"岡脇, 誠","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山村, 真弘","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"山口, 佳之","creatorNameLang":"ja"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KATATA, Yosuke","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAGASAKA, Takeshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SANO, Fuminori","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TANIOKA, Hiroaki","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OKAWAKI, Makoto","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAMURA, Masahiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAGUCHI, Yoshiyuki","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-04-01"}],"displaytype":"detail","filename":"KMJ-J202147061.pdf","filesize":[{"value":"1.5 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","objectType":"fulltext","url":"https://kwmed.repo.nii.ac.jp/record/2988/files/KMJ-J202147061.pdf"},"version_id":"4a0e0553-c6cd-4995-8cc8-b0e053f9047a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"がん遺伝子パネル検査","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"Tumor mutational burden","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"大腸癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"Nivolumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Hyper progressive disease","subitem_subject_scheme":"Other"},{"subitem_subject":"Cancer gene panel test","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Tumor mutational burden","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Colon cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Nivolumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Hyper progressive disease","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Tumor mutational burden 高値を根拠にnivolumab 導入も hyper progressive disease に至ったマイクロサテライト安定大腸癌の１例","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Tumor mutational burden 高値を根拠にnivolumab 導入も hyper progressive disease に至ったマイクロサテライト安定大腸癌の１例","subitem_title_language":"ja"}]},"item_type_id":"10001","owner":"31","path":["800"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-04-01"},"publish_date":"2022-04-01","publish_status":"0","recid":"2988","relation_version_is_last":true,"title":["Tumor mutational burden 高値を根拠にnivolumab 導入も hyper progressive disease に至ったマイクロサテライト安定大腸癌の１例"],"weko_creator_id":"31","weko_shared_id":-1},"updated":"2024-04-19T04:22:10.746536+00:00"}